Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
NICE recommends more frequent injections (alternate days until no further improvement) for patients with neurological involvement
Use appropriate weight measuring equipment.
An analysis of six clinical trials found that AOD 9604 had a safety profile comparable to placebo and did not act through the IGF-1 pathway
Stimulates Lipolysis Prompts fat cells to break stored triglycerides into free fatty acids the body can burn for fuel Inhibits Lipogenesis Slows the creation of new fat, working both sides of the fat-storage equation No IGF-1 Rise Isolates the fat-metabolism fragment, so it does not raise IGF-1 or drive tissue growth No Glucose Disruption In studies it did not impair insulin sensitivity or affect blood sugar the way full GH can In laboratory and animal work, the fragment behaved as designed
